BEIGENE-BGB-11417-103
Phase I/II
OPEN TO ACCRUAL
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients with Myeloid Malignancies
JNJ-75276617ALE1001
Phase I/II
OPEN TO ACCRUAL
A Phase 1/2, First-in-Human Study of the Menin-KMT2A (MLL1) Inhibitor Bleximenib in Participants with Acute Leukemia
ORYZON-CL04-ORY-1001
Phase I
OPEN TO ACCRUAL
An Escalation/Expansion, Open Label, Multicenter Study of Iadademstat and Gilteritinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like Tyrosine Kinase Mutation (FLT3 Mut+): The FRIDA Study
UAB-19113-NTX-301
Phase I
OPEN TO ACCRUAL
A Phase 1 Study of NTX-301, an Oral DNMT1 Inhibitor, in Patients with MDS and AML